Alizée Hugede
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alizée Hugede has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Amandine Robac
EA3830 GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, 76000 Rouen, France
1 shared publication - Elisabeth Garrido
EA3830 GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, 76000 Rouen, France
1 shared publication - Lionel Nicol
Institut national de la santé et de la recherche médicale (INSERM), Endothelium, Valvulopathy & Heart Failure (ENVI) U1096, Normandie Université, Rouen, France (M.S., Y.S., L.N., P.M.).
1 shared publication - Nicolas Guérout
Université Paris Cité, CNRS UMR8003, Saints-Pères Paris Institute for the Neurosciences, Paris, France
1 shared publication - Pauline Neveu
Saints Pères Paris Institute for the Neurosciences, Université Paris Cité, CNRS UMR8003, 75006 Paris, France
1 shared publication - Quentin Delarue
EA3830 GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, UNIROUEN, 76000 Rouen, France
1 shared publication
Latest Publications
- Open Access
- 3 December 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1827
Repetitive Trans Spinal Magnetic Stimulation Improves Functional Recovery and Tissue Repair in Contusive and Penetrating Spinal Cord Injury Models in Rats
Spinal cord injury (SCI) is an incurable condition in which the brain is disconnected partially or completely from the periphery. Mainly, SCIs are traumatic and are due to traffic, domestic or sport accidents. To date, SCIs are incurable and, most of the time, leave the patients with a permanent loss of sensitive and motor functions. Therefore, for several decades, researchers have tried to develop treatments to cure SCI. Among them, recently, our lab has demonstrated that, in mice, repetitive trans-spinal magnetic stimulation (rTSMS) can, after SCI, modulate the lesion scar and can induce functional locomotor recovery non-invasively. These results are promising; however, before we can translate them to humans, it is important to reproduce them in a more clinically relevant model. Indeed, SCIs do not lead to the same cellular events in mice and humans. In particular, SCIs in humans induce the formation of cystic cavities. That is why we propose here to validate the effects of rTSMS in a rat animal model in which SCI leads to the formation of cystic cavities after penetrating and contusive SCI. To do so, several techniques, including immunohistochemical, behavioral and MRI, were performed. Our results demonstrate that rTSMS, in both SCI models, modulates the lesion scar by decreasing the formation of cystic cavities and by improving axonal survival. Moreover, rTSMS, in both models, enhances functional locomotor recovery. Altogether, our study describes that rTSMS exerts positive effects after SCI in rats. This study is a further step towards the use of this treatment in humans.
- 3 December 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1827
Open AccessRepetitive Trans Spinal Magnetic Stimulation Improves Functional Recovery and Tissue Repair in Contusive and Penetrating Spinal Cord Injury Models in Rats
Spinal cord injury (SCI) is an incurable condition in which the brain is disconnected partially or completely from the periphery. Mainly, SCIs are traumatic and are due to traffic, domestic or sport accidents. To date, SCIs are incurable and, most of the time, leave the patients with a permanent loss of sensitive and motor functions. Therefore, for several decades, researchers have tried to develop treatments to cure SCI. Among them, recently, our lab has demonstrated that, in mice, repetitive trans-spinal magnetic stimulation (rTSMS) can, after SCI, modulate the lesion scar and can induce functional locomotor recovery non-invasively. These results are promising; however, before we can translate them to humans, it is important to reproduce them in a more clinically relevant model. Indeed, SCIs do not lead to the same cellular events in mice and humans. In particular, SCIs in humans induce the formation of cystic cavities. That is why we propose here to validate the effects of rTSMS in a rat animal model in which SCI leads to the formation of cystic cavities after penetrating and contusive SCI. To do so, several techniques, including immunohistochemical, behavioral and MRI, were performed. Our results demonstrate that rTSMS, in both SCI models, modulates the lesion scar by decreasing the formation of cystic cavities and by improving axonal survival. Moreover, rTSMS, in both models, enhances functional locomotor recovery. Altogether, our study describes that rTSMS exerts positive effects after SCI in rats. This study is a further step towards the use of this treatment in humans.